Figure 2.
Over 50 ABL kinase domain mutations have been identified with differential potency of the tyrosine kinase inhibitors imatinib, dasatinib and nilotinib.58,59 Selected mutations are depicted.
Abbreviations: IC, inhibitory concentration.
Over 50 ABL kinase domain mutations have been identified with differential potency of the tyrosine kinase inhibitors imatinib, dasatinib and nilotinib.58,59 Selected mutations are depicted.
Abbreviations: IC, inhibitory concentration.
